U.S. Hospitality Stock News

Oxbridge Re Holdings, through its SurancePlus subsidiary, previously announced an agreement with HCI Group to issue three Solana-based tokenized reinsurance securities tied to contracts underwritten by HCI’s Fortex Reinsurance SPC, alongside new reinsurance agreements for the 2026–2027 catastrophe coverage period. This pairing of blockchain-enabled access to reinsurance risk with refreshed catastrophe protection highlights HCI Group’s experimentation with new capital channels and...

Recently, Zacks upgraded Brink's to a Rank #2 (Buy), citing a positive shift in analyst earnings estimates and a stronger earnings outlook for the company. This ratings change highlights how revisions to profit expectations can shape investor perception of Brink's evolving cash-management and digital services business model. Next, we'll examine how this more optimistic earnings outlook might influence Brink's broader investment narrative built around AMS and digital solutions. The future of...

Stock move and recent performance context John Wiley & Sons (WLY) has drawn investor interest after a recent move that left the stock at $44.39, with returns of 1% over the past day and 3% over the past week. Over the past month the stock shows a 10% gain, and over the past 3 months it is up 22%. Year to date, John Wiley & Sons has returned 50%, while the 1 year total return stands at 18%. See our latest analysis for John Wiley & Sons. The recent move to a share price of $44.39 comes after a...

Earlier this week, Vornado Realty Trust reported that PENN 2 in New York’s PENN DISTRICT is now 90% leased after signing 10–12 year full-floor agreements with technology tenants Veeva and Altana AI, which is establishing its new headquarters there. This leasing progress at a flagship redevelopment, coupled with increased interest across office REITs, highlights how high-quality, amenity-rich assets may be attracting tenants even as the broader office sector adjusts to new working...

On June 8, 2026, PTC Therapeutics announced that board member Alethia Young resigned to focus on other work commitments, while simultaneously entering a consulting agreement that keeps her advising the company through June 8, 2027. This move comes as PTC Therapeutics reports record revenue driven by strong global uptake of SEPHIENCE, underscoring the company’s emphasis on continuity of commercial and advisory expertise. We’ll now examine how record SEPHIENCE-driven revenue, alongside Alethia...

In May 2026, Maximus, Inc. entered into a second amendment to its Amended and Restated Credit Agreement, securing an additional US$325,000,000 in Tranche B-1 term loans with terms matching its existing term B facilities. The new borrowing, earmarked for revolver repayment, share repurchases, working capital, and related fees, highlights Maximus’ active use of leverage to fund capital returns while maintaining liquidity. We’ll now examine how Maximus’ expanded term loan capacity and planned...

Blue Owl Capital recently opened a new office in the Abu Dhabi Global Market, establishing a Middle East regional headquarters to deepen relationships with sovereign wealth funds, family offices, and institutional investors. At the same time, Blue Owl’s ability to raise US$500,000,000 in investment-grade debt for its flagship credit fund under elevated redemption pressure highlights both investor demand for its products and the liquidity management questions it must address. We’ll now...

CG Oncology (CGON) is back in focus as investors look ahead to key data from its Phase 3 PIVOT-006 trial and a planned regulatory filing for bladder cancer therapy cretostimogene later this year. See our latest analysis for CG Oncology. Recent excitement around cretostimogene and upcoming conference appearances has not prevented some volatility, with the share price down 20.77% over the past month and 12.78% over 90 days, yet still posting a 31.42% year to date share price return and a very...

Rising tensions between the US and Iran, self defense strikes, and related crude supply disruptions have pushed oil prices higher, putting Diamondback Energy (FANG) firmly back on investors’ radar as a key US shale producer. See our latest analysis for Diamondback Energy. Short term, the stock has been choppy, with the share price falling 6.67% over the past week even as it gained 11.04% over 90 days and delivered a 35.39% total shareholder return over the past year. This pattern suggests...

Tarsus Pharmaceuticals recently presented at the 46th Annual William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, highlighting its eye-care portfolio and commercial progress. These conferences gave the company a high-visibility forum to emphasize growing real-world adoption of XDEMVY, supported by intensive direct-to-consumer marketing efforts. We’ll now examine how accelerating XDEMVY awareness and uptake, spotlighted at these...

In recent days, Clear Street analyst Tim Moore highlighted Willdan Group’s potential upside, citing expected revenue and adjusted EBITDA growth from power grid modernization and rising demand for energy-efficient and AI datacenter solutions, while company insiders sold about US$6.1 million of stock over the past three months. This combination of bullish analyst commentary on AI datacenter exposure and concurrent insider selling offers a contrasting signal about management’s and the market’s...

Garrett Motion (GTX) is back in focus after shareholders approved the election of Jeffrey Vanneste to the board, as the stock continues to post strong sector outperformance and attract positive earnings sentiment. See our latest analysis for Garrett Motion. Recent news around Jeffrey Vanneste joining the board comes against a backdrop of strong share price momentum, with a 30 day share price return of 9.75%, a 90 day gain of 80.98%, and a 1 year total shareholder return of 217.92%. This...

Dutch Bros recently reported first-quarter 2026 results that met earnings expectations and exceeded revenue forecasts, prompting management to raise its 2026 outlook for revenues, same-shop sales growth, and adjusted EBITDA while continuing rapid new shop openings and rolling out its food program. At the same time, Dutch Bros’ continued push into new markets like Rockford, Illinois, and its expanding food offering highlight both its growth ambitions and the operational and cost execution...

Atai Beckley N.V. recently reported first-quarter results and a business update, confirming it remains on track to advance BPL-003 into a Phase 3 pivotal program and to report topline Phase 2 data for VLS-01 in the fourth quarter of this year. This progress underscores how Atai Beckley is steadily moving multiple psychedelic-based treatments through late-stage development, potentially broadening its clinical footprint across different psychiatric indications. We’ll now examine how the...

The Providence Group, a subsidiary of Green Brick Partners, recently completed the 2026 Atlanta St. Jude Dream Home® Giveaway house and opened it for public tours, while U.S. lawmakers advanced a revised housing bill restricting institutional purchases of single-family homes. Together, these developments highlight Green Brick Partners’ blend of community-focused philanthropy and a vertically integrated homebuilding model that could be positioned differently under changing housing...

Why Graham’s latest earnings and guidance matter for investors Graham (GHM) has drawn fresh attention after reporting record fourth quarter and full year 2026 revenue, along with new fiscal 2027 net sales guidance of US$285 million to US$295 million and commentary on profitability. See our latest analysis for Graham. The mixed reaction to Graham’s record results and 2027 guidance has pulled the share price back recently, with a 7 day share price return of 7.52% decline and a 30 day share...

On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal. This collaboration highlights growing external interest in casdatifan as a potential component of combination regimens,...

On 9 June 2026, Raymond James Financial presented at the Morgan Stanley US Financials Conference in New York and announced the appointment of Seth Ford as Senior Vice President, Chief Architect, to lead the firm’s technology architecture evolution across its platforms. By bringing in Ford, who has decades of experience in financial services technology at Vanguard and Fidelity, Raymond James is signaling a deeper commitment to integrating AI, advanced analytics and modern cloud architecture...

Popular (BPOP) is back in focus after recent analyst commentary highlighted upward revisions to earnings estimates and a strong momentum style score. This has drawn attention to how these signals may influence sentiment around its stock. See our latest analysis for Popular. Recent price action has been supportive for that improving sentiment, with a 90 day share price return of 19.32% and a 1 year total shareholder return of 51.92%. Multi year total shareholder returns above 100% point to...

Madison Square Garden Sports (MSGS) is under fresh scrutiny after a very public clash with New York City officials over crowd limits and security for the Knicks’ NBA Finals Game 4 watch party. See our latest analysis for Madison Square Garden Sports. Despite the public clash with city officials, investors have focused on performance in the background, with the share price at $386.37 and a 49.26% year to date share price return alongside a 102.03% 1 year total shareholder return that points to...

In recent days, Mastercard received preliminary court approval for a very large US$38 billion merchant settlement over credit card processing fees and launched its Agent Pay for Machines platform to enable AI agents and machines to execute automated, micro-payment transactions across its global network. Taken together, the settlement’s new rules on interchange and Mastercard’s push into machine‑initiated payments highlight how the network is reshaping both its regulatory footing and its...

NRG Energy (NRG) is back in focus after weaker-than-expected quarterly profitability and a sharp 6.9% single-day share decline, as investors weigh leverage, cost control questions, and ongoing debt refinancing activity. See our latest analysis for NRG Energy. That sharp 7.2% one day share price drop to US$120.65 sits on top of a wider slide, with the 30 day share price return down 12.13% and the year to date share price return down 27.39%. This is occurring even though the 3 year total...

In early June 2026, Alkermes reported a narrower-than-expected first-quarter loss and stronger revenue, supported by higher sales of Vivitrol, Aristada, Lybalvi, and newly acquired Lumryz, while reaffirming its full-year revenue guidance despite increased R&D and acquisition-related spending. By pairing solid proprietary product trends with encouraging new data for orexin agonist alixorexton, the company is increasingly framing sleep medicine as a core pillar of its evolving business...

Yelp’s antitrust push against Google puts search power in the spotlight Yelp (YELP) is pressing its antitrust case against Google, arguing that Google’s dominance in search should require broader access to its search index and user interaction data for rival services. The company is asking the court to rely on earlier findings about Google’s market power instead of revisiting them. Google, in contrast, argues that AI tools and more localized search trends mean the current market needs a fresh...